Genetic Interaction Mapping Platform
Sector
TechBio
Company
Emerging TechBio
Therapeutic Area
Platform
Treatment Modality
Genetic Interaction Mapping
Product Stage
Series B
Expertise
Partnering
A TechBio innovator developed an AI-driven platform that mapped genetic interaction networks to identify novel therapeutic targets across oncology and rare disease. Despite deep scientific credibility, investors struggled to parse the technical language of functional genomics into clear implications for drug discovery value. The challenge was to communicate computational biology with the same clarity and evidentiary weight as a traditional therapeutic story—anchoring abstract science in tangible outcomes.
Situation
A TechBio innovator developed an AI-driven platform that mapped genetic interaction networks to identify novel therapeutic targets across oncology and rare disease. Despite deep scientific credibility, investors struggled to parse the technical language of functional genomics into clear implications for drug discovery value. The challenge was to communicate computational biology with the same clarity and evidentiary weight as a traditional therapeutic story—anchoring abstract science in tangible outcomes.
Situation
Approach
We implemented a med-comms-informed investor narrative that translated platform complexity into a structured investment thesis. This began with developing a unified lexicon to describe the approach in investor-friendly terms while preserving scientific depth. We prioritized communications that connected computational predictions to experimentally validated outputs, reinforced through data visuals and cross-modality use cases. Supporting materials for investor meetings and deal roadshows emphasized scalability, precision, and partnership potential, linking biological insight directly to pipeline and licensing economics.
We implemented a med-comms-informed investor narrative that translated platform complexity into a structured investment thesis. This began with developing a unified lexicon to describe the approach in investor-friendly terms while preserving scientific depth. We prioritized communications that connected computational predictions to experimentally validated outputs, reinforced through data visuals and cross-modality use cases. Supporting materials for investor meetings and deal roadshows emphasized scalability, precision, and partnership potential, linking biological insight directly to pipeline and licensing economics.
Approach
Results
The integrated communications strategy helped reposition the company from “AI hype” to “AI-enabled discovery engine.” By uniting scientific storytelling and investor communications under one credible narrative, the platform gained traction with pharma BD teams and institutional investors, catalyzing new partnership discussions.
The integrated communications strategy helped reposition the company from “AI hype” to “AI-enabled discovery engine.” By uniting scientific storytelling and investor communications under one credible narrative, the platform gained traction with pharma BD teams and institutional investors, catalyzing new partnership discussions.
Situation
A TechBio innovator developed an AI-driven platform that mapped genetic interaction networks to identify novel therapeutic targets across oncology and rare disease. Despite deep scientific credibility, investors struggled to parse the technical language of functional genomics into clear implications for drug discovery value. The challenge was to communicate computational biology with the same clarity and evidentiary weight as a traditional therapeutic story—anchoring abstract science in tangible outcomes.
Approach
We implemented a med-comms-informed investor narrative that translated platform complexity into a structured investment thesis. This began with developing a unified lexicon to describe the approach in investor-friendly terms while preserving scientific depth. We prioritized communications that connected computational predictions to experimentally validated outputs, reinforced through data visuals and cross-modality use cases. Supporting materials for investor meetings and deal roadshows emphasized scalability, precision, and partnership potential, linking biological insight directly to pipeline and licensing economics.
Results
The integrated communications strategy helped reposition the company from “AI hype” to “AI-enabled discovery engine.” By uniting scientific storytelling and investor communications under one credible narrative, the platform gained traction with pharma BD teams and institutional investors, catalyzing new partnership discussions.
*Impact studies reflect the collective experience of Biography and its partners.
Other Work
Let's Partner
Generating the
Biology Century
We help life sciences teams cut through complexity and move from biology to belief—sharper, faster, leaner.
Let's Partner
Generating the
Biology Century
We help life sciences teams cut through complexity and move from biology to belief—sharper, faster, leaner.
Let's Partner
Generating the
Biology Century
We help life sciences teams cut through complexity and move from biology to belief—sharper, faster, leaner.